ICU Medical, Inc. — FY 2014 Form 10-K
Business context and period. The filing covers the fiscal year ended December 31, 2014; it is an annual report, not a standalone Q4 filing. ICU Medical develops and sells medical devices for infusion therapy, critical care and oncology, with products sold in more than 60 countries. The company reports one operating segment.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $309.3 million | $313.7 million |
| Gross profit / margin | $151.4 million / 49.0% | $154.7 million / 49.3% |
| Operating income / margin | $39.0 million / 12.6% | $51.9 million / 16.6% |
| Net income | $26.3 million | $40.4 million |
| Diluted EPS | $1.68 | $2.65 |
| Cash from operations | $60.6 million | $65.7 million |
| Cash, equivalents and investments at year-end | $346.8 million | $296.9 million |
| Working capital at year-end | $408.5 million | $367.4 million |
Capital expenditures were $16.6 million. Investing activities used $21.8 million; financing activities provided $19.3 million. The balance sheet reports no borrowings or other debt. Current liabilities were $28.7 million against current assets of $437.2 million. Stockholders’ equity was $508.3 million.
Material changes versus the prior year
- Revenue declined 1.4%; operating income fell about 24.9%, and net income fell about 34.8%.
- Infusion Therapy sales decreased 2% to $216.0 million, principally as U.S. Hospira orders declined. Critical Care rose 1% to $55.1 million; Oncology was nearly flat at $36.9 million.
- International sales increased to $96.6 million from $90.6 million, while domestic sales declined to $212.6 million from $223.1 million.
- R&D expense rose to $18.3 million from $12.4 million. Restructuring and strategic transaction charges totaled $5.1 million, versus $1.4 million in 2013.
- The effective tax rate increased to 33.8% from 23.3%. Foreign currency translation reduced other comprehensive income by $11.7 million.
Outlook, commentary and risks
- Management estimated 2015 capital expenditures of $12–14 million and stated that available cash, investments and expected operating cash flows should fund operations for at least the next 12 months. No revenue or earnings guidance was provided.
- Management attributed lower gross margin to product mix and temporary product-line rework, partly offset by lower logistics costs. The 2014 restructuring reduced the workforce by 69; $1.4 million remained accrued at year-end, with most expected to be paid in Q1 2015.
- Hospira represented 36% of worldwide revenue in 2014 and 27% of year-end receivables. The company said Hospira had reduced U.S. infusion purchases in both 2013 and 2014. In February 2015, Pfizer announced its planned acquisition of Hospira, expected to close in the second half of 2015; ICU Medical expected its agreements to survive the transaction.
- Key risks include reliance on Hospira and Clave products, competition and pricing pressure, regulatory and product-liability exposure, patent disputes or expirations, foreign exchange and international operations, and dependence on manufacturing capacity in Salt Lake City, Mexico and Slovakia. Certain critical materials are sourced from sole suppliers.
- The company repurchased $5.6 million of stock during 2014 and had $22.5 million remaining under its repurchase authorization. It has not paid dividends and does not anticipate doing so in the foreseeable future.
Important facts for investors to verify
- Track Hospira order trends, the outcome and integration effects of Pfizer’s acquisition, and the status of the supply and distribution agreements that extend through 2018.
- Assess whether higher R&D spending and new products can offset continued pressure on infusion sales and operating margins.
- Review 2015 capital spending, operating cash flow, and the use of the substantial cash and investment balance, including repurchases and potential acquisitions.
- Monitor the impact of foreign exchange movements, customer receivable concentration, and any supply, manufacturing, regulatory, litigation or product-quality developments.
- For Q4 specifically, revenue was $79.9 million and net income was $7.4 million, compared with $77.9 million and $13.3 million, respectively, in Q4 2013; diluted EPS was $0.46 versus $0.86.
Assurance: Deloitte & Touche issued unqualified opinions on the financial statements and internal control over financial reporting as of December 31, 2014.